Pilot trial suggests structured support may help limit weight regain after GLP-1 treatment

AI Summary

A pilot randomized trial suggests structured support may reduce early weight regain after patients stop GLP-1 receptor agonist treatment for obesity. Treatment discontinuation is common for reasons including cost, coverage limitations, side effects, and patient preference.

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference and other factors—and often leads to rapid weight regain. Results from a pilot randomized trial, published in Obesity Science & Practice, suggest that structured support may attenuate early weight gain after GLP-1 cessation.